Free Trial

Olema Pharmaceuticals (OLMA) Competitors

Olema Pharmaceuticals logo
$4.71 +0.14 (+3.06%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$4.71 0.00 (0.00%)
As of 07/25/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OLMA vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALT

Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

Olema Pharmaceuticals vs. Its Competitors

Harrow (NASDAQ:HROW) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-10.19% -25.01% -4.27%
Olema Pharmaceuticals N/A -42.31%-38.32%

Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$212.86M6.24-$17.48M-$0.56-64.63
Olema PharmaceuticalsN/AN/A-$129.47M-$2.01-2.34

In the previous week, Harrow had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 7 mentions for Harrow and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.89 beat Harrow's score of 0.90 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Harrow Positive
Olema Pharmaceuticals Very Positive

72.8% of Harrow shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

Harrow presently has a consensus price target of $63.83, suggesting a potential upside of 76.38%. Olema Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 420.17%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Harrow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Olema Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Harrow and Olema Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OLMA vs. The Competition

MetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$312.68M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-2.3421.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book0.668.378.665.87
Net Income-$129.47M-$55.19M$3.25B$258.55M
7 Day Performance6.80%5.88%4.22%3.73%
1 Month Performance3.29%17.33%10.51%11.75%
1 Year Performance-69.48%4.42%34.40%18.03%

Olema Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OLMA
Olema Pharmaceuticals
2.4171 of 5 stars
$4.71
+3.1%
$24.50
+420.2%
-67.9%$312.68MN/A-2.3470
HROW
Harrow
2.5561 of 5 stars
$35.62
+2.0%
$63.83
+79.2%
+49.4%$1.31B$199.61M-63.61180
PAHC
Phibro Animal Health
4.0907 of 5 stars
$31.54
+2.4%
$24.40
-22.6%
+55.0%$1.28B$1.02B40.441,940Positive News
ABCL
AbCellera Biologics
2.235 of 5 stars
$4.24
+5.7%
$8.75
+106.4%
+64.8%$1.27B$28.83M-7.57500High Trading Volume
COGT
Cogent Biosciences
3.5614 of 5 stars
$11.09
+1.0%
$18.00
+62.3%
+30.9%$1.26BN/A-6.0380High Trading Volume
PHVS
Pharvaris
1.4393 of 5 stars
$23.80
-5.3%
$36.20
+52.1%
+18.2%$1.24BN/A-7.9130News Coverage
High Trading Volume
NTLA
Intellia Therapeutics
4.5235 of 5 stars
$11.95
+3.6%
$33.37
+179.2%
-48.5%$1.24B$57.88M-2.28600News Coverage
Insider Trade
CVAC
CureVac
4.7545 of 5 stars
$5.46
flat
$6.83
+25.2%
+50.0%$1.22B$579.18M5.93880Positive News
AUPH
Aurinia Pharmaceuticals
2.9761 of 5 stars
$9.04
+2.7%
$11.50
+27.2%
+59.5%$1.22B$235.13M32.29300Upcoming Earnings
WVE
WAVE Life Sciences
4.4813 of 5 stars
$7.84
+1.8%
$20.50
+161.5%
+33.3%$1.22B$108.30M-9.33240
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180

Related Companies and Tools


This page (NASDAQ:OLMA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners